ZGNX News and Press, Zogenix Inc. From 05/05/20

Zogenix (NASDAQ: ZGNX ): Q1 GAAP EPS of -$0.54 beats by $0.54 . Revenue of $1.25M beats by $0.87M . Press Release More news on: Zogenix, Inc., Earnings news and commentary, Healthcare stocks news,

FDA PDUFA target action date of June 25, 2020, for FINTEPLA® NDA in Dravet syndrome Plan to meet with FDA in second half of 2020 to discuss planned FINTEPLA Lennox-Gastaut syndrome sNDA Closed public offering of common stock for net proceeds of $221.7 million; approximately $42...

Zogenix Inc. (NASDAQ: ZGNX) was featured in a recent equity research report published by Mizuho Securities USA LLC. The report reads, “Zogenix hosted a KOL event on 4/22. The most important data point in our view was the updated long-term data from FINTEPLA in Dravet syndrome, which rei...

EMERYVILLE, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close, and will host...

EMERYVILLE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor conference call and webcast on two studies evaluating its investigational drug, FINTEPLA®...

Noteworthy events during the week of March 22 - 28 for healthcare investors (some could be canceled/postponed due to COVID-19). More news on: Bristol-Myers Squibb Company, Zogenix, Inc., Heron Therapeutics, Inc., Healthcare stocks news, , Read more ...

The cannabis industry is projected to grow rapidly over the next few years, but companies looking to profit from this trend have several headwinds to deal with. One of these issues is the fact that the regulatory environment surrounding cannabis-based products is still a bit shaky. However, on...

Don't call GW Pharmaceuticals (NASDAQ: GWPH) and  Corbus Pharmaceuticals (NASDAQ: CRBP)  "pot stocks." These legitimate drug developers seek to harness the body's endocannibinoid pathways to treat serious diseases.    GW made headlines in 2018 when the Food and Drug Ad...

Business disruptions due to COVID-19 represent a new risk for investors across all sectors. Expect to see language addressing this added to the risk factors section of 10-K annual reports filed with the Securities and Exchange Commission (SEC). For biotech and pharma companies, COVID-19 will im...

If you are young and you drink a great deal it will spoil your health, slow your mind, make you fat - in other words, turn you into an adult. "- P. J. O'Rourke Today, we take a developmental biotech company whose stock has been hit hard both by recent disappointing study results as well a...